Leap Therapeutics has announced a $58.89 million capital raise through a public equity private placement (PIPE), spearheaded by Winklevoss Capital. The NASDAQ-listed company plans to finalize the transaction by October 8. The funds will be allocated to establish a digital asset treasury. As part of the agreement, Winklevoss Capital gains the right to nominate two members to Leap's board, including the board chair.